VIP/VPAC Receptor Modulators for Neurodegeneration

VIP/VPAC Receptor Modulators for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">VIP/VPAC Receptor Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Aviptadil (RL-001)</td>
<td>VPAC1/VPAC2</td>
</tr>
<tr>
<td class="label">Ro 25-1392</td>
<td>VPAC2</td>
</tr>
<tr>
<td class="label">BAY 55-9837</td>
<td>VPAC1/VPAC2</td>
</tr>
</table>

VIP/VPAC Receptor Modulators for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">VIP/VPAC Receptor Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Aviptadil (RL-001)</td>
<td>VPAC1/VPAC2</td>
</tr>
<tr>
<td class="label">Ro 25-1392</td>
<td>VPAC2</td>
</tr>
<tr>
<td class="label">BAY 55-9837</td>
<td>VPAC1/VPAC2</td>
</tr>
</table>

Vasoactive intestinal peptide (VIP) receptor modulators represent a promising therapeutic approach for neurodegenerative diseases. VIP signals through VPAC1 and VPAC2 receptors, G protein-coupled receptors (GPCRs) of the secretin family, to exert neuroprotective, anti-inflammatory, and immunomodulatory effects["@harmar2012"]. This page covers drug candidates, clinical development status, and delivery strategies for VIP-based therapies in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and related disorders.

Therapeutic Rationale

Neuroprotective Mechanisms

VIP receptor activation produces multiple neuroprotective effects:

• cAMP/PKA/CREB signaling: Promotes expression of neurotrophic factors including BDNF[@gozes2009]
• PI3K/Akt pathway: Inhibits GSK-3β, prevents tau phosphorylation, blocks apoptosis
• Anti-inflammatory effects: Suppresses NF-κB, shifts microglia to M2 phenotype, reduces pro-inflammatory cytokines
• Synaptic plasticity: Enhances LTP, increases dendritic spine density
• Mitochondrial protection: Preserves Complex I activity, reduces oxidative stress

Disease-Specific Rationale

Alzheimer's Disease

VIP-based therapies address core AD pathology through multiple mechanisms[@brenneman2003][@pass2006]:

• Amyloid modulation: Reduces Aβ-induced neurotoxicity, promotes non-amyloidogenic APP processing
• Tau pathology: VIP-activated Akt inhibits GSK-3β, reducing tau phosphorylation
• Synaptic dysfunction: Enhances hippocampal plasticity and cognitive function
• Neuroinflammation: Suppresses microglial activation and pro-inflammatory cytokine production
• Cholinergic protection: Protects basal forebrain cholinergic neurons

Parkinson's Disease

VIP offers dopaminergic neuroprotection through[@offen2000][@samaranch2014][@kong2012]:

• Dopaminergic neuron protection: Reduces 6-OHDA and MPTP toxicity
• Alpha-synuclein modulation: May reduce aggregation, enhance autophagy clearance
• Neuroinflammation: Suppresses microglial activation in substantia nigra
• Blood-brain barrier protection: Preserves BBB integrity

Amyotrophic Lateral Sclerosis

VIP provides motor neuron protection in ALS models[@nguyen2001]:

• Extends survival in SOD1 mutant mice
• Protects against glutamate-induced excitotoxicity
• Modulates glial responses
• Reduces harmful microglial activation

Huntington's Disease

VIP shows promise in HD models[@maqbool2013]:

• Reduces mutant huntingtin (mHTT) aggregation
• Counteracts transcriptional dysregulation
• Enhances BDNF expression
• Improves motor function

Drug Candidates

Peptide Agonists

Aviptadil (RL-001)

Aviptadil is a synthetic 28-amino acid VIP analog that has undergone clinical testing:

• Mechanism: Mixed VPAC1/VPAC2 agonist
• Clinical experience: Tested in respiratory and inflammatory conditions; safety established in >1,000 subjects
• Neurodegeneration potential: Shown to cross the blood-brain barrier in animal models
• Current status: Being investigated for repurposing in AD and PD

Delivery Strategies

Challenges

VIP-based therapeutics face significant delivery challenges[@bundgaard2012][@kumar2015]:

• Short half-life: VIP circulates with t½ < 2 minutes due to proteolytic degradation
• Blood-brain barrier: Limited passive diffusion requires active transport strategies
• Receptor desensitization: VPAC receptors internalize with chronic exposure

Approaches

• Intranasal delivery: Bypasses the blood-brain barrier for direct nose-to-brain transport
• Peptide engineering: D-amino acid substitutions, cyclization for enhanced stability
• Gene therapy: AAV-mediated VIP delivery for long-term expression
• Focused ultrasound: Temporary BBB opening for enhanced delivery

Comparison with Related Approaches

GLP-1 Receptor Agonists

VIP/VPAC modulators share similarities with GLP-1 receptor agonists:

• Both are neuroprotective peptides
• Activate cAMP/PKA pathways
• Reduce neuroinflammation
• Clinical trials ongoing for both

• VIP has broader receptor distribution
• GLP-1 agonists have better clinical track record
• VIP has stronger immunomodulatory effects

Side Effects and Safety

VIP-based therapies have shown favorable safety profiles:

• Common: Mild flushing, headache, nausea
• Hypotension: Due to VPAC-mediated vasodilation
• Hypoglycemia: VPAC1 affects insulin secretion

Contraindications

• VIPoma (VIP-producing tumors)
• Uncontrolled diabetes
• Severe cardiovascular disease

Related Pages

• [VIP Signaling Pathway in Neurodegeneration](/mechanisms/vip-vasoactive-intestinal-peptide-signaling-neurodegeneration)
• [Vipr1 Protein](/proteins/vipr1-protein)
• [Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)
• [GLP-1 Receptor Agonists for Neurodegeneration](/therapeutics/glp-1-receptor-agonists-neurodegeneration)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;